

Panama

Population 2018

4.2 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	2.2 (1.6–2.7)	52 (39–65)
HIV-positive TB incidence	0.4 (0.3–0.51)	9.5 (7.1–12)
MDR/RR-TB incidence ^{oo}	0.075 (0.031–0.14)	1.8 (0.75–3.3)
HIV-negative TB mortality	0.22 (0.21–0.24)	5.4 (5.1–5.7)
HIV-positive TB mortality	0.082 (0.056–0.11)	2 (1.3–2.7)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	2.1% (0.69–4.3)
Previously treated cases	17% (8.9–29)

TB case notifications, 2018

Total new and relapse	1 723
- % tested with rapid diagnostics at time of diagnosis	49%
- % with known HIV status	99%
- % pulmonary	84%
- % bacteriologically confirmed ^{ooo}	71%
- % children aged 0-14 years	7%
- % women	33%
- % men	60%
Total cases notified	1 837

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	14% (11–18)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	314	18%
- on antiretroviral therapy	314	100%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	59%
- Previously treated cases	47%
Laboratory-confirmed cases*	MDR/RR-TB: 48, XDR-TB: 1
Patients started on treatment**	MDR/RR-TB: 48, XDR-TB: 1
MDR/RR-TB cases tested for resistance to second-line drugs	48

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	73%	1 874
Previously treated cases, excluding relapse, registered in 2017	35%	94
HIV-positive TB cases registered in 2017	55%	340
MDR/RR-TB cases started on second-line treatment in 2016	35%	40
XDR-TB cases started on second-line treatment in 2016		

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	26%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100%

TB financing, 2019

National TB budget (US\$ millions)

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females ■ Males Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically